Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.
In Science this week: genetic study of Homo floresiensis, approach for counting immune cells based on DNA signatures, and more.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
Public sector programs in some low- and middle-income countries will obtain access to Hologic's Panther system through a single, all-inclusive pricing structure.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.
Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
The Associated Press reports that researchers are applying gene-editing approaches to HIV treatment.
The researchers noted that this is the first time CRISPR was used to mutate a restriction factor in order to confer innate antiviral function to human cells.
The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.
Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.
NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.
In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.